Molecular Oncology

OCT 20, 2026 · JOURNAL ARTICLE

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology

Angiogenesis is a major driver of tumor progression and a validated therapeutic target in highly vascularized cancers such as clear cell renal cell carcinoma. However, the clinical

OCT 15, 2026 · JOURNAL ARTICLE

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology

Transcription factors (TFs) are often considered undruggable due to their structural complexity. mRNA technologies can overcome this therapeutic limitation by enabling dynamic prot

OCT 6, 2026 · JOURNAL ARTICLE

Targeting the EpCAM ‐ AXL axis to overcome drug resistance in lung cancer

Molecular Oncology

Drug resistance significantly limits the long-term effectiveness of targeted therapies in lung cancer. AXL, a receptor tyrosine kinase (RTK), is a well-established driver of drug r

SEP 7, 2026 · REVIEW

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

Molecular Oncology

A systematic review synthesizing evidence on biomarkers for BCG therapy prediction in bladder cancer; provides a landscape assessment rather than a new empirical result, identifying gaps and promising directions for clinical practice.

SEP 7, 2026 · JOURNAL ARTICLE

Gut microbiota alterations in patients with non‐small‐cell lung cancer undergoing chemoradiotherapy

Molecular Oncology

Observational microbiota profiling study in a single cohort showing modest associations with survival outcomes, lacking a control group and powered only to detect compositional differences, not clinical prediction.

SEP 7, 2026 · JOURNAL ARTICLE

Profiling neoadjuvant therapy response in rectal cancer using meta‐analysis of publicly available transcriptomic RNA ‐seq datasets

Molecular Oncology

Meta-analysis of public transcriptomic data identifying candidate biomarkers and immune signatures associated with neoadjuvant response in rectal cancer, but without clinical validation, prospective design, or outcome prediction model.